Resumen

RIERA, J.A.; MUSURUANA, J.L.; COSTA, C.A.  y  CAVALLASCA, J.A.. Development of psoriasis during treatment with Abatacept in rheumatoid arthritis. Rev. argent. reumatolg. [online]. 2019, vol.30, n.2, pp.33-35. ISSN 0327-4411.

Abatacept is the first biological agent approved for the treatment of Rheumatoid Arthritis (RA) that acts blocking interaction of T lymphocytes. Although its efficacy in psoriasis and psoriatic arthritis has been reported, there are reports of drug induced psoriasis as well as reactivation of cutaneous lesions. A woman with a history of RA under treatment with Abatacept IV presented erythematous-scaly and pruritic macules on the entire body surface, clinically and histologically compatible with psoriasis. The suspension of treatment with Abatacept caused the disappearance of the cutaneous lesions. More than 4 years later he is in treatment with Rituximab without presenting cutaneous lesions.

Palabras clave : psoriasis; Abatacept; arthritis.